Two murine monoclonal antibodies (CL-3 and CL-37, both F(ab')2) to human endothelial-leukocyte adhesion molecule-i (ELAM-1) were found to react immunohistochemically with rat pulmonary artery endothelial cells that had been pretreated with tumor necrosis factor (TNFa). CL-3, but not CL-37, blocked in vitro adherence ofneutrophils to TNFa-treated endothelial cells and the killing of TNFa-treated rat endothelial cells by phorbol ester activated neutrophils. In rats treated systemically with CL-3, there was a 70% reduction in accumulation of neutrophils in glycogen-induced peritoneal exudates.
Introduction
Two murine monoclonal antibodies (CL-3 and CL-37, both F(ab')2) to human endothelial-leukocyte adhesion molecule-i (ELAM-1) were found to react immunohistochemically with rat pulmonary artery endothelial cells that had been pretreated with tumor necrosis factor (TNFa). CL-3, but not CL-37, blocked in vitro adherence ofneutrophils to TNFa-treated endothelial cells and the killing of TNFa-treated rat endothelial cells by phorbol ester activated neutrophils. In rats treated systemically with CL-3, there was a 70% reduction in accumulation of neutrophils in glycogen-induced peritoneal exudates. Treatment of animals with CL-37 anti-ELAM-1 did not reduce neutrophil accumulation under the same conditions. When IgG immune complex deposition was induced in dermis and in lungs of rats, treatment with CL-3 anti-ELAM-1 markedly reduced vascular injury as measured by changes in vascular permeability (leakage of 1251-albumin) and hemorrhage (extravasation of 51Cr-red blood cells). The protective effects of CL-3 anti-ELAM-1 were related to greatly diminished recruitment ofneutrophils (as assessed morphologically, by tissue extraction of myeloperoxidase, and by retrieval, via bronchoalveolar lavage, of neutrophils from lung). CL-37 had no protective effects in vivo after deposition of immune complexes in lung. Using either CL-3 or CL-37 anti-ELAM-1, immunohistochemical analysis of lungs undergoing IgG immune complex-induced injury revealed a striking upregulation of ELAM-1 in the lung vasculature (venules and interstitial capillaries), with a peak intensity developing between 3 and 4 h after deposition of immune complexes in lung. Vascular beds of spleen, liver, and kidney failed to show upregulation of ELAM-1 under these same conditions. The immunohistochemical reactivity of rat lung was abolished if the anti-ELAM-1 preparation was first absorbed with monolayers of human umbilical vein endothelial cells that had been pretreated with TNFa. Untreated human endothelial cells failed to cause loss oflung reactivity ofthe anti-ELAM-1 preparation. These data indicate that ELAM-1 is upregulated in the pulmonary vasculature of rats during deposition of immune complexes and that ELAM-1 appears to play an obligate role in the recruitment of neutrophils. (J. Clin. Invest. 1991. 88:1396-1406.) Key words: endothelial cells * tumor necrosis factor aimmune complexes * endothelial leukocyte adhesion molecule-1 * neutrophils Adhesion molecules appear to play critical roles in the recruitment of neutrophils to sites of inflammation. The need for the CD18 integrins is most clearly shown by the fact that neutrophil accumulation at sites of bacterial infection is profoundly reduced in patients with CD18 deficiency (1) . The use of murine MAbs to CD1 8 and to intercellular adhesion molecule-l (anti-ICAM-l)' in various animal models has also demonstrated that CD1 8 integrins and ICAM-I are required for neutrophil accumulation at inflammatory sites (2) (3) (4) . However, recent evidence indicates that CDl 8-independent mechanisms are also linked to emigration of neutrophils in some inflammatory conditions involving the lung (2, 5) . Results from studies in vitro indicate that CDl 8-independent neutrophil-endothelial adhesion may involve members of the lectin cellular adhesion molecule (LEC-CAM) (Selectin) family ofadhesion molecules (6) (7) (8) (9) (10) (11) . While there are no published studies in vivo showing that endothelial-leukocyte adhesion molecule-l (ELAM-1) and granular membrane protein-140 (GMP-140) are involved in neutrophil localization, Jutila et al. (12) have shown that a MAb (MEL-14) to a third member of the LEG-CAM family, LEC-CAM-l leukocyte adhesion molecule-1 (LAM-1), in the mouse markedly reduces the number of neutrophils in experimental peritoneal inflammation.
This study addresses the hypothesis that ELAM-I may play a role in the localization ofneutrophils at sites ofacute imflammation. The experiments involve the evaluation of two antihuman ELAM-1 immune monoclonal antibodies (CL-3 and CL-37) that cross-react with an antigen expressed on cultured, tumor necrosis factor (TNF)a-stimulated rat pulmonary artery endothelial cells. Evidence is provided that these antibodies recognize rat ELAM-1 at sites ofacute inflammation, and that one of the MAbs (CL-3) greatly diminishes that accumulation of neutrophils and attenuates the injury after deposition ofIgG immune complexes in the rat lung and skin.
Methods
Reagents. Unless otherwise indicated, all reagents were purchased from Sigma Chemical Co., St. Louis, MO.
Monoclonal antibodies. Antibodies directed against ELAM-l were generated by immunization of BALB/c mice with human umbilical vein endothelial cells (HUVEC) which had been stimulatedwith recombinant human IL-I B for 3 h at 37°C. Mouse hybridomas were prepared in the usual manner (13) , and supernatant fluids containing IgG were screened for their ability to react exclusively with stimulated (IL-1j, 4 h, 37°C) HUVEC, using immunoperoxidase technology. Three hybrid- omas, CL-2, CL-3, and CL-37 (all IgG1) were subcloned. These antibodies partially inhibited binding of human neutrophils to IL-1,8 stimulated permeability and reacted (as assessed by flow cytometry) with COS and L cells transfected with cDNA for ELAM-l but not with cells transfected with irrelevant cDNA (Kishimoto, K. I., and C. W. Smith, unpublished data). The ELAM-l cDNA in the CDM8 expression vector (14) was kindly provided by Dr. B. Seed (Harvard University, Boston, MA). The MAbs exhibited little or no reactivity (by immunoperoxidase) with unstimulated HUVEC, bound maximally to HUVEC stimulated by IL-I# for 4 h, and exhibited little reactivity with stimulated HUVEC at 24 h. None of the MAbs bound to human or rat platelets, neutrophils, monocytes, or lymphocytes as determined by flow cytometry (data not shown). Furthermore, as assessed by flow cytometric analysis, CL-3 anti-ELAM-l failed to react either with ADP-stimulated rat platelets or with N'-FMLP-stimulated rat blood neutrophils (data not shown). F(ab')2 preparations were made using the ImmunoPure F(ab')2 preparation kit (Pierce Chemical Co., Rockford, IL).
The control (irrelevant) monoclonal antibody consisted of F(ab')2 fragments derived from pepsin digestion of MOPC 21 (mouse myeloma, IgG,). For the immune complex studies of lung and dermal vascular injury, a total of 135 gg anti-ELAM-I (CL-3 and 37) or irrelevant F(ab')2 was injected intravenously in three equally divided doses at 2.5, 3.0, and 3.5 h after intravenous injection ofBSA and intratracheal instillation or intradermal injection of anti-BSA (which consisted of rabbit polyclonal IgG rich in antibody to bovine serum albumin, anti-BSA). Unless otherwise noted, negative control animals were injected intradermally or intratracheally with anti-BSA, but the intravenous injection of BSA was omitted.
Animal models ofimmune complex alveolitis and dermal vasculitis. Rabbit polyclonal IgG rich in anti-BSA was used to induce lung and dermal vascular injury (15) . IgG was purchased from Organon Teknika, West Chester, PA). The IgG anti-BSA and BSA (Sigma Chemical Co., St. Louis, MO) preparations that were used for injection into rats contained 20 pg/ml and 12 pg/ml ofendotoxin activity, respectively, as measured by the limulus amebocyte lysate assay (E-toxate, Sigma Chemical Co.). 300-350 g male Long-Evans specific pathogen-free rats (Charles River Breeding Laboratories, Inc., Wilmington, MA) were used for all studies. Intraperitoneal ketamine (25-50 mg/100 g body wt) and sodium pentobarbital (5 mg/100 g body wt) were administered for sedation and anesthesia. Immune complex lung injury was induced by the intravenous injection of 10 mg BSA (in 1.0 ml saline) and the intratracheal instillation of anti-BSA in 300 ,l. The following intratracheal doses of anti-BSA were used: 0.75 mg, 1.50 mg, 2.50 mg, or 3.33 mg. Rats were killed 4 h after injury and the pulmonary circulation was flushed with 10 ml saline via pulmonary arterial injection. Permeability indices, as a measure oflung injury, were determined by comparing leakage of '25I-labeled albumin into lung parenchyma to the amount remaining in 1.0 ml of blood. Reversed passive dermal Arthus reactions were induced by intradermal injection of0. 10-0.84 mg anti-BSA contained in a volume of0.10 ml, followed by intravenous injection of 10 mg BSA in 1.0 ml saline. Rats were killed 4 h thereafter and permeability indices calculated by measuring the ratio ofradioactivity present in full thickness skin biopsies compared to radioactivity present in 1.0 ml ofblood. Negative controls included animals with intradermal sites injected with anti-BSA but with the omission of intravenous injection of BSA.
For assessment of lung or dermal hemorrhage, red blood cells (RBC) were harvested from heparinized blood obtained from normal adult Long-Evans rats. 9 ml blood was diluted with 40 ml saline containing 1:1,000 heparin. To this was added 100 MCi 51Cr, followed by incubation for 1 h at 37°C with continuous shaking. After centrifugation at 1,000 rpm (at 4°C) for 6 min, cells were washed in PBS three times and were then ready for use. The same injury and treatment protocols were used as described above for immune complex-induced lung and skin injury. Animals were injected with 51Cr-labeled RBC (45 ,l containing 80,000 cpm) 1/2 h before injection ofBSA and anti-BSA. At the time of killing, skin sites and saline-perfused lungs were measured for 5"Cr radioactivity and compared to counts present in 1.0 ml of blood. At the conclusion ofeach experiment, blood samples from each animal were centrifuged and radioactivity measured in the cells and serum. No radioactivity counts above background levels were detected in the sera from animals injected with 5"Cr RBC (data not shown).
Glycogen-induced peritoneal exudates. Neutrophil-rich exudates were elicited in rat peritoneal cavities with the injection of 25 ml 0.1% (wt/vol) oyster glycogen 4 h before killing. 135 Mg F(ab')2 anti-ELAM-1, was injected intravenously in three equally divided doses in the treatment group (at 2.5, 3.0, and 3.5 h) to assess effects on neutrophil recruitment into peritoneal cavities.
Tissue myeloperoxidase (MPO) content. A standard reference curve was first established by measuring MPO in lungs and skin sites that had been injected with known numbers of neutrophils. For our studies, lung and skin sites were extracted by homogenization and sonication procedures that have been previously described (16) . MPO activity in supernatants was measured by the change in optical density (at 460 nm) resulting from decomposition ofH202 in the presence ofo-dianisidine.
Immunohistochemical analysis ofcells and lungtissue. Monolayers of rat pulmonary artery endothelial cells (RPAEC) on plastic slides were stimulated with 50 ng/ml human recombinant TNFa for 4 h, washed with PBS, and fixed with acetone. Slides containing monolayers of stimulated or unstimulated cells were then incubated with CL-3 or CL-37 anti-ELAM-l (1.0 ng/ml) for 45 min. The slides were then washed with PBS and then stained for bound MAb using the biotin/avidin-peroxidase system for mouse IgG (Vectastain; Vector Laboratories Inc., Burlingame, CA). After hematoxylin counterstaining, sections were coated with aqua-mount (Lerner Laboratories, Pittsburgh, PA) and examined by light microscopy for the presence ofreaction products ofperoxidase. Immune complex-induced lung injury was accomplished using the same protocols described above. Animals were killed at 0, 1, 2, 3, and 4 h. The lungs were inflated with 8-9 ml of optimal cutting temperature (OCT) compound (Miles Laboratories Inc., Elkhart, IN) and frozen sections obtained from lungs of normal rats and those undergoing intraalveolar deposition of immune complexes. After mounting on poly-L-lysine coated slides and fixation with acetone, tissue sections were then reacted with the anti-ELAM-I preparation, as described above.
An additional experiment was also carried out using the same staining procedure, and using lung from the 4-h immune complex reaction. Before use, the CL-3 preparation (1.0 ng/ml) was incubated for I h at 27°C with monolayers (5 x 106 cells) of TNFa-50 ng/ml)-stimulated or unstimulated HUVEC, preceding application of antibody to the lung sections. This was done to assess whether TNFa-stimulated HU-VEC would remove antibody reactivity.
Morphologic evaluation oflungs and skin. Lungs were fixed in 10% phosphate buffered formalin for subsequent hematoxylin and eosin staining and examination by light microscopy. Skin samples were similarly treated.
Neutrophil-mediated cytotoxicity of endothelial cells. Neutrophilmediated cytotoxicity of RPAEC was measured by a standard 5"Cr release assay (17) . RPAEC were seeded into a 24-well culture dish, with S X 104 cells per well in 1 ml culture medium. Each well received 2 MCi ofNa5"CrO4 (New England Nuclear, Boston, MA) and the monolayers were then incubated for 14 h. TNFa was then added at a concentration of 50 ng/ml and monolayers were incubated for an additional 4 h. The plates were then washed twice with HBSS containing 0.02% BSA to remove the nonincorporated radioactivity. The endothelial cell monolayers were then ready for use. When antibodies (CL-2, CL-3, CL-37 MAbs) were employed, they were added to the monolayers and incubated for 30 min. Human blood neutrophils were isolated (see below) and suspended in HBSS supplemented with 0.02% BSA. Neutrophils were then added to duplicate wells to give effector to target cell ratios of 30:1 in a final volume of 1.0 ml. Neutrophils were allowed to settle onto the endothelial cell monolayers for 30 min before the addition ofphorbol myristate acetate (PMA) (50 ng/ml) which was added in a volume of 0.1 ml per well. After an additional incubation at 370C for 6 h, 0.9 ml supernatant was removed from each well and any cells in suspension removed by centrifugation. The supernatant fluid (0.5 ml) was aspirated and assayed in a y-scintillation counter to determine 5"Cr release. Spontaneous release was determined using fluids from wells receiving medium only. Total release of "Cr was achieved by addition of0.2% Triton X-100. The median spontaneous release never exceeded 20% ofthe total release and in most experiments ranged between 5 and 15% of the total release. The cytotoxicity was calculated by the following formula:
.
.yo t experimental release -spontaneous release % cytotoxicity = --X 100. total release -spontaneous release Isolation ofblood neutrophils. Heparinized whole blood (rat or human) diluted 1:1 with PBS was layered onto Ficoll-Hypaque (specific gravity 1.077), centrifuged (400 g, 30 min) and the red blood cell layer containing the neutrophils incubated in a lysing solution of NH4C1 (17) . The neutrophils were then washed and resuspended in HBSS. Differential counts using crystal violet staining of the nuclei revealed that > 95% of the cells were neutrophils. Neutrophils were then stimulated in vitro with FMLP (100 nM), immune complexes (containing 15 ,ug antibody/ml), or PMA (20 ng/ml), and the O2 responses measured by superoxide dismutase-inhibitable reduction offerricytochrome c. In the case ofstimulation of rat neutrophils with FMLP or immune complexes, cytochalasin B (Sigma Chemical Co.) was added (5 Rg/ml) to accentuate the 0 responses (18) .
Rat neutrophils were also used to examine the effects ofCL-3 anti-ELAM-I on neutrophil chemotactic responses using the leading front method for quantitation (19 
Results
Protection by anti-EL4M-1 against neutrophil-mediated killing ofrat pulmonary artery endothelial cells. Both F(ab')2 CL-3 and CL-37 anti-ELAM-l were evaluated for their effects on adhesion of human neutrophils to RPAEC that had first been exposed for 4 h to human recombinant TNFa (50 ng/ml). After washing, irrelevant F(ab')2 or CL-3 or CL-37 anti-ELAM-1 (F(ab')2) were added (50 ,ug/ml) for 1 (20) . The cytotoxic effects on these endothelial cells are known to be related to the generation by neutrophils oftoxic oxygen products (17) . MAbs (CL-2, CL-3, CL-37)
were used at a final concentration of 15 gg/ml and were added to the endothelial cell monolayers immediately before addition of human neutrophils. The endpoint was release of 5"Cr 4 h later from the endothelial cells which had been previously exposed to TNFa (50 ng/ml) for 4 h before washing and addition ofneutrophils and PMA (20 ng/ml). As is evident from the data in Table I , only CL-3 antibody to human ELAM-1 was able to suppress the cytotoxic effects of activated neutrophils (by 80%). As will be shown below, using immunoperoxidase techniques, CL-3 and CL-37 were equally reactive with rat pulmonary artery endothelial cells that had been pretreated with TNFa and also reacted with lung tissue sections 4 h after in vivo deposition of immune complexes.
Inhibition by anti-ELAM-J of neutrophil accumulation in glycogen-inducedperitoneal exudates. Neutrophil-enriched exudates (containing > 90% neutrophils) were induced in rat peritoneal cavities by the injection 4 h earlier of 0.1% (wt/vol) oyster glycogen in PBS. When employed, F(ab')2 CL-3 or CL-37 anti-ELAM-1 was injected intravenously in three equally divided doses (45 ,ug each) at 2.5, 3.0, and 3.5 h. As is evident by the data in Fig. 1 , there was a significant reduction (70%) in numbers of neutrophils accumulating in the peritoneal cavities of rats treated with CL-3 anti-ELAM-l as compared to those animals treated with irrelevant F(ab')2 ("positive control" group) (Fig. 1) . The negative control group consisted of rats that had been intraperitoneally injected with saline (in the absence of glycogen) into the peritoneal cavity and then treated with irrelevant F(ab')2. As expected, few neutrophils were recruited under these conditions. Treatment of rats with CL-37 Figure 1 . Effects of treatment of rats with F(ab')2 anti-ELAM-l (CL -3 and CL-37) on accumulation ofneutrophils (PMN) after intraperitoneal instillation of glycogen. Cells were harvested at 4 h. The negative control rat was injected intraperitoneally with sterile saline. The positive controls were treated with irrelevant F(ab')2 or anti-ELAM-I preparations. The data were analyzed with a one-way ANOVA (P < 0.001), the positive antibody and the negative controls demonstrating P < 0.001. anti-ELAM-l did not reduce the numbers of neutrophils recruited in response to instillation of glycogen into peritoneal cavities of rats (Fig. 1) . It would appear that CL-3 may react at least in part with an ELAM-I epitope that blocks interaction with the sial LeJ moiety on the neutrophils (21-23), whereas CL-37 reacts with a functionally irrelevant epitope on ELAM-1.
Anti-ELAM-1 relatedprotection against immune complexinduced vascular injury. Acute vascular injury was induced in rat lung and skin after local injection of antibody (anti-BSA) and intravenous injection of BSA. As described above, four different doses of anti-BSA were used in lung and skin to achieve a range of injury. Endpoints for injury were leakage of '25I-albumin and extravasation into tissue of 51Cr-RBC. Since acute injury in the lung commonly results in increased intravascular pressure which can be associated with increases in vascular surface area and possible recruitment ofadditional capillaries, the hemorrhage index was also used in most of the studies, since this represents an unequivocal parameter of vascular injury. Rats were treated either with three equal doses (45 Ug each) of CL-3 anti-ELAM-l (present as F(ab')2) or with irrelevant F(ab')2, each dose being injected intravenously at 2.5, 3.0, and 3.5 h after initiation of immune complex reactions. The results are shown in Figs. 2 and 3 . In the lung, the anti-BSA concentrations of0.75, 1.50, 2.50, and 3.33 mg produced progressive increases in vascular permeability proportional to the amount ofanti-BSA injected into positive control animals (Fig.  2 A) . In animals treated with CL-3 anti-ELAM-l, there were significant reductions in vascular permeability (Fig. 2 A) . When the two groups were compared, using anti-BSA doses of 0.75, 1.50, 2.50, and 3.33 mg, treatment with anti-ELAM-l led treated animals as compared to the positive controls that had been treated with irrelevant F(ab')2 (Fig. 2 B) . Companion studies were done using the model of dermal vascular injury and employing a range ofconcentrations (0.1O, 0.21, 0.42, and 0.84 mg) of anti-BSA per skin site. Again, rats were treated either with irrelevant F(ab')2 (control animals) or with CL-3 anti-ELAM-l, as described above. The results in Fig.  3 A indicate that vascular injury as expressed by leakage of albumin was proportional to the dose of anti-BSA employed. In animals treated with anti-ELAM-1, there were significant reductions in the increased vascular permeability at all doses of anti-BSA employed. When comparisons between these two 0.8-A. Leakage (Fig. 3 B) .
Reduction of neutrophil accumulation in lungs after immune complex deposition in anti-ELAM-I treated animals. To assess if the protective effects of F(ab')2 CL-3 anti-ELAM-l could be related to attenuation of tissue accumulation of neutrophils after deposition ofimmune complexes, protocols similar to those described above were employed, using a range of concentrations of anti-BSA. In the lung, there were significant reductions (> 50%) in the amounts of tissue extractable MPO at all four concentrations ofanti-BSA employed when animals had been treated with CL-37 anti-ELAM-l, as compared to treatment ofrats with irrelevant F(ab')2 (Fig. 4 A) . At each dose of antibody, the difference between the anti-ELAM-l treated and untreated groups was statistically significant. The lack ofa dose-response relationship between the amount of anti-BSA used and the amount of extractable MPO from lung probably reflects the relatively high doses ofanti-BSA used as compared to results in the skin where much lower concentrations of anti-BSA were used (see below).
When skin sites injected with 0.10-0.84 mg anti-BSA were also evaluated for extractable MPO content, a proportionality between dose ofanti-BSA and skin content ofMPO was noted, with a plateau occurring at the two highest doses of anti-BSA (Fig. 4 B) . In animals treated with CL-3 anti-ELAM-I (as compared to animals treated with irrelevant F(ab')2), there was a statistically significant reduction in the amount of MPO at each dose of anti-BSA used (Fig. 4 B) figure) . Two-way ANOVA ofthe skin MPO data (B) revealed P < 0.001. Additional t tests reveal significant difference between positive control and CL-3 treated groups at doses of 0.1 mg (P < 0.01), 0.21 mg (P = 0.01), 0.42 mg (P = 0.008), and 0.84 mg (P = 0.01) anti-BSA.
Immunohistochemical analysis ofpulmonary artery endothelial cells and pulmonary vasculature for ELAM-J. Monolayers ofRPAEC were exposed to either 50 ng/ml recombinant human TNFa or HBSS for 4 h, washed, and then incubated (45 min) with CL-3 anti-ELAM-(F(ab')2) (1.0 ng/ml), followed by immunoperoxidase staining, according to procedures described above. RPAEC that had been exposed to TNFa showed a high degree of reactivity (Fig. 6 A) whereas cells not exposed to TNFa showed little or no evidence of staining (Fig. 6 B) . These data indicate that CL-3 anti-ELAM-l detects a TNFainducible product in RPAEC. The time course of induction of ELAM-l reactivity in TNFa-treated RPAEC, as assessed by immunoperoxidase reactivity, revealed little or no staining during the first 2 h, but intense staining at 3 and 4 h (data not shown). When CL-37 anti-ELAM-l was used, the results in staining of rat pulmonary artery endothelial cells were similar to the data obtained with CL-3 (data not shown). Additional p'c 001 studies were designed to determine if, by immunohistochemical analysis oflung tissue, there was observable upregulation in the appearance ofELAM-l-reactivity during the time course of immune complex-induced lung injury. Intraalveolar immune "-* complex deposition was produced in the usual manner, using 3.33 (Fig. 6 c) . At TREATMENT GROUP Figure 5 . Retrieval of neutrophils from lung by bronchoalveolar lavage after immune complex deposition and treatment of rats with irrelevant F(ab')2 or anti-ELAM-l F(ab')2. The negative controls, which received 2.5 mg anti-BSA intratracheally but no BSA intravenously, had a mean yield of neutrophils of < 2 x 10'. The positive controls had a mean yield of 104±3.6 x 105 while positive controls treated with anti-ELAM-I had a yield that was reduced by 47%. One-way ANOVA for all the data yielded P < 0.001. Additional t tests revealed significant difference between positive controls and negative controls P < 0.006, positive controls and CL-3 treated rats (P = 0.0 17), and negative controls and CL-3 treated animals P < 0.001. clear evidence ofstaining within alveolar septal walls The intense staining of alveolar septal walls is consistent with reactivity ofcapillary endothelial cells. The frozen section technique did not permit a higher degree of morphological resolution. Attempts to date to obtain staining oflung tissue that has been fixed in paraformaldehyde or phosphate-buffered formaldehyde have not been successful (data not shown). The staining oflung sections obtained 4 h after immune complex deposition was unaffected if the anti-ELAM-l preparation was reacted with nonstimulated HUVEC (frame g), but the staining oflung tissue was abolished if anti-ELAM-l was first absorbed with HUVEC monolayers that had been preincubated for 4 h with TNFa (frame h). These findings indicate a remarkably increased reactivity ofthe rat lung vasculature with anti-ELAM-I antibody in a time course that requires several hours after initiation of immune complex deposition before maximal staining with CL-3 occurs. These features are consistent with the known in vitro time course for upregulation of ELAM-l in HUVEC (9) and suggest that this upregulation in the rat pulmonary vasculature is required for the recruitment of neutrophils into sites of immune complex deposits. The time course in expression of ELAM-l in rat lung is remarkably consistent with a similar pattern of upregulation of ELAM-l in rat pulmonary artery endothelial cells incubated in vitro with TNFa (see above).
Endothelial-Leukocyte
When frozen sections of liver, kidney, and spleen were obtained from rats 4 h after immune complex deposition in lungs, immunoperoxidase staining with CL-3 anti-ELAM-l failed to demonstrate expression of ELAM-1 in any of these extrapulmonary tissues (data not shown).
Morphological correlates ofprotective effects ofanti-ELAM-1. Light microscopy was used to evaluate changes 4 h after deposition of immune complexes in skin and lung, using 0.42 and 2.50 mg anti-BSA, respectively. The data in Figs. 4 Fig. 7 . The intradermal sites in animals treated with irrelevant F(ab')2 showed the usual dense infiltration ofvenular walls with neutrophils as well as the presence of neutrophils and RBC in the edematous interstitial connective tissue (frame a). In striking contrast, skin sites from animals treated systemically with CL-3 anti-ELAM-1 demonstrated very few neutrophils in any location and there was little or no evidence of edema or hemorrhage in pervascular areas (frame b). In lungs from positive reference control animals, there was extensive intraalveolar hemorrhage, fibrin deposition, and accumulation of neutrophils (frame c), in contrast to CL-3 anti-ELAM-l treated rats in which the alveolar compartment contained very few RBC, neutrophils, and fibrin deposits (frame d). The precise geography of neutrophil localization in these lungs, involving endothelial cell-adherent neutrophils versus transmigrated neutrophils, is not currently known. A complete analysis to define the location these neutrophils in the pulmonary vasculature is currently underway.
Based on tissue extraction ofMPO and morphological analysis, CL-3 ELAM-I is, therefore, highly protective against immune complex-induced injury, its protective effects being correlated with greatly diminished influx of neutrophils.
Absence ofsuppressive effects ofanti-ELAM-I on neutrophil function. The protective effects of CL-3 anti-ELAM-l could conceivably be due to an unexpected reactivity ofthe antibody with neutrophils. Two different approaches were used to address this question. First, we observed the effects of anti-ELAM-I infusion (three separate intravenous infusions of 45 Mig each, as described above) on blood neutrophil counts in normal rats and in those undergoing immune complex deposition in lung. For the 90-min interval after the third infusion of anti-ELAM-l, there was no decrease in the total blood leukocyte count or in the neutrophil count (data not shown). Assuming no extravascular equilibration or renal excretion of this molecule (both assumptions being exceedingly unlikely), the plasma concentration of anti-ELAM-l would be -7 jg/ml. Accordingly, for some ofthe in vitro studies, concentrations of 7 ,ug/ml or greater were used (see below).
Second, we assessed the extent to which CL- Inability ofCL-37 anti-ELAM-I to protect against immune complex-induced lung injury. To control for the effects ofCL-3 anti-ELAM-1, another F(ab')2 anti-ELAM-1, CL-37, was used. As indicated above, CL-37 anti-ELAM-l neither blocked the cytotoxic effects on RPAEC of phorbol ester activated neutrophils (Table I) , nor did it block recruitment of neutrophils into peritoneal cavities injected with glycogen ( Fig. 1) . Based on immunohistochemical analysis, CL-37 anti-ELAM-l was at least as reactive as CL-3 in the staining of RPAEC that had been exposed for 4 h to TNFa (data not shown). CL-37 antibody was also highly reactive with sections from lungs 4 h after immune complex deposition (data not shown), similar to the findings in Fig. 6 (e and ] ) where CL-3 was used. However, when the same protocol that had been used with CL-3 anti-ELAM-l (Fig. 2) was used for assessment of effects of CL-37 anti-ELAM-I on immune complex-induced lung injury after airway instillation of 2.50 mg anti-BSA, CL-37 was without any protective effects (Fig. 8) . Thus, while both antibodies are reactive with TNFa-treated RPAEC and with lung sections from animals developing immune complex-induced injury, only one (CL-3) of the two antibodies to ELAM-l was protective in vivo against immune complex induced lung injury.
Discussion
The significantly protective effects of CL-3 anti-ELAM-l in interference with the influx into tissues of neutrophils (Figs (Table I) . Consistent with this observation, CL-37 neither protected against IgG immune complex-induced lung injury (Fig.  8) nor did it interfere with recruitment of neutrophils into glycogen-injected peritoneal cavities (Fig. 1) . These data suggest that, while CL-37 is reactive with ELAM-1, reactivity is to an epitope not involved in adhesive interactions between rat neutrophils and pulmonary vascular endothelial cells.
The data in this paper may be relevant to a recent observation in rats that also underwent IgG immune complex-induced alveolitis. Bronchoalveolar fluid from these animals was found to contain high levels of TNFa. When animals were treated with antibody to TNFa, such that no TNFa biological activity could be detected in bronchoalveolar fluids, the lungs were dramatically protected from injury. This protection was related to a greatly diminished influx of neutrophils (16) . Such observations, together with the data in this paper, suggest that immune complex deposition triggers in lung the release of TNFa, which then causes upregulation of ELAM-I in pulmonary venules and septal capillaries. These events would then appear to facilitate the adherence of neutrophils to endothelial cells containing upregulated amounts of ELAM-I on their cell surfaces, after which neutrophil emigration presumably occurs in response to C5a that has been generated within alveoli. In recent studies, we have demonstrated that, if rats undergoing intrapulmonary deposition of IgG immune complexes are also treated with antibody to TNFa, this results in a lack of upregulation of ELAM-1 in the pulmonary microvasculature, a finding consistent with the lack of influx of neutrophils (Mulligan, M. S., and P. A. Ward, submitted for publication).
The complexities in defining the in vivo role of adhesionpromoting molecules are apparent in this report. Although both CL-37 and CL-3 are highly reactive immunohistochemically with cytokine-stimulated RPAEC, only the latter blocks in vitro killing of RPAEC by stimulated neutrophils and only CL-3 has in vivo protective effects. Had the in vivo experiments been carried out exclusively with CL-37, conclusions might have been drawn that ELAM-l plays no role in either neutrophil recruitment or in the ultimate expression of tissue injury, and that the expression ofELAM-1 in tissues is an interesting but irrelevant curiosity. Accordingly, negative results in biological systems using monoclonal antibodies to adhesion molecules must be interpreted with caution. Simple technical problems such as the critical timing for infusion of the anti-ELAM-l antibodies (F(ab')2) also need to be taken into account in the event of a negative result. Indeed, in pilot studies in which CL-3 F(ab')2 anti-ELAM-l was infused shortly after BSA injection, little protection was found (data not shown). The rapid clearance of this protein, together with the knowledge that the most intense intrapulmonary expression of ELAM-l occurs 3 and 4 h after deposition of immune complexes (Fig. 6 ), explains the negative result and the critical timing for infusion of anti-ELAM-1. Finally, although intact IgG, anti-ELAM-l antibodies would overcome the problem of in vivo rapid clearance, we have found them to be unreliable. In fact, using intact IgG, CL-3 anti-ELAM-l, in vitro injury to RPAEC by phorbol ester stimulated human neutrophils actually accentuated, and immune complex injury to lung (of the type described in this report) was also accentuated (data not shown), presumably due to engagement of FcyR receptors of neutrophils and/or (in the case of in vivo studies ofdeveloping immune complex-induced lung injury) complement fixation on the surface of endothelial cells, leading to direct endothelial cell injury by the membrane attack complex, C5b-9.
Although there are abundant data indicative of the role of ELAM-l in adhesive interactions between lymphocytes and neutrophils and cytokine-stimulated endothelial cells in vitro (7, 11, (25) (26) (27) (28) (29) , its role in vivo previously had not been assessed. ELAM-1 is expressed on venular endothelial cells in humans at sites of acute (29) and chronic (28) inflammation, and in primates at skin sites following cytokine injection (30) . While it is not clear what role ELAM-1 may play in chronic inflammation, its presence at skin sites where the inflammatory infiltrate consists predominantly of mononuclear leukocytes supports the observations in vitro that ELAM-l may also serve as an adhesion molecule for lymphocytes (27, 28, 31) . Our results provide the first evidence that ELAM-l participates in some acute inflammatory reactions and plays a pivotal role in neutrophil extravasation and injury in immune complex-induced lung inflammation. This is of particular interest in light of recent evidence that there are CD1 8-independent mechanisms of neutrophil immigration into the lungs of rabbits (5), humans (2) , and rats (Mulligan, M.S., et al., submitted for publication).
